Genomic Testing in Women with Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Author and Disclosure Information [Show]

Sima Ehsani, MD
Assistant Professor of Medicine, Division of Hematology/Medical Oncology, University of Arizona Cancer Center, Tucson, AZ

Kari Braun Wisinski, MD
Associate Professor, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI

Question 1 of 5

A 48-year-old premenopausal woman presents with a mammogram-detected right breast invasive ductal carcinoma (IDC), grade II, positive for both estrogen and progesterone receptors (ER and PR) and HER2-negative. Ki-67 is 15%. She undergoes a partial mastectomy and sentinel lymph node biopsy (SLNB), with pathology showing a 2.1-cm tumor, no lymphovascular invasion, negative margins, and 1 out of 2 SLNs positive for metastasis. Complete blood count and comprehensive metabolic panel are unremarkable.

Which of the following tests will help estimate this patient’s risk for distant breast cancer recurrence?

A baseline serum CA 27-29

Ki-67 assay

21-gene assay (Oncotype DX)

None of the above, as the prognostic value of genomic tests has not been validated in node-positive breast cancers

Hospital Physician: Hematology/Oncology. 2017 November;12(6)

This quiz is not accredited for CME.

More from Board Review Questions: Hematology/Oncology

QUIZ

Management of Metastatic Gastric Cancer
Transfusion Medicine
Small Cell Lung Cancer
Management of Colorectal Cancer in Older Adults
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease
Acute Myeloid Leukemia
Pancreatic Adenocarcinoma: Advanced Unresectable and Metastatic Disease
HER2-Positive Breast Cancer
Aggressive B-Cell Non-Hodgkin Lymphoma
Von Willebrand Disease: Clinical Management
Von Willebrand Disease: Assessment and Diagnostic Testing
Pancreatic Adenocarcinoma: Neoadjuvant and Adjuvant Treatment
Late Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Polycythemia Vera and Essential Thrombocythemia: Current Management
Treatment of Biliary Tract Cancers
Early Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Hairy Cell Leukemia
Immune Thrombocytopenia
Cancer-Related Fatigue
Disseminated Intravascular Coagulation
Advanced Stage and Relapsed/Refractory Hodgkin Lymphoma
Adjuvant Chemotherapy for Colon Cancer
Molecular Markers and Targeted Therapies in the Management of Non-Small Cell Lung Cancer
Metastatic Cutaneous Melanoma: Targeted Therapy and Immunotherapy
Thrombosis in Pregnancy
Locally Advanced Pancreatic Cancer
Early-Stage Hodgkin Lymphoma
Neoadjuvant and Adjuvant Therapy for Gastric Cancer
Hemophilia A and B
Mantle Cell Lymphoma
Soft Tissue Sarcoma
Sickle Cell Disease
Renal Cell Carcinoma
Management of Locally Advanced Rectal Adenocarcinoma
Adjuvant Systemic Therapy for Early-Stage Breast Cancer
Chronic Myeloid Leukemia
Plasma Cell Disorders
Myelodysplastic Syndromes
Acute and Chronic Graft-versus-Host Disease